Abstract

Cancer development and progression can be regulated by the levels of endogenous factors. Gastric cancer is an aggressive disease state with poor patient prognosis, needing the development of new diagnostics and therapeutic strategies. We investigated the close association between follistatin-like 3 (FSTL3) and different cancers, and focused on its role in gastric cancer cell function. Using cancer bioinformatics, we found that FSTL3 expression is elevated in a large majority of the 33 cancers we analyzed in publicly available cancer databases. Elevated levels of FSTL3 is associated with poor patient prognosis in gastric cancer. In a comparison of normal gastric epithelial cells and gastric cancer cell lines, FSTL3 expression was consistently elevated in gastric cancer cells. Overexpression of FSTL3 promoted gastric cancer cell viability, proliferation and migration. Conversely, FSTL3 knockdown inhibits these cellular processes. Using bioinformatics, we found that the FSTL3 mRNA has a potential binding site in the 3’-UTR for a small microRNA, miR-486-5p. Further bioinformatics revealed significant negative correlation between FSTL3 and miR-486-5p levels. Using luciferase reporter constructs, we provide evidence that the 3’UTR from the FSTL3 mRNA can confer downregulation in the presence of miR-486-5p. These studies lead us to conclude that FSTL3 has oncogenic properties and increased expression of this gene product promotes gastric cancer development and progression.

Highlights

  • Gastric cancer is one of the most common malignant cancers with serious consequences for population health and mortality

  • follistatin-like 3 (FSTL3) expression is associated with gastric cancer and poor patient prognosis

  • We evaluated the clinical implications of FSTL3 expression in gastric cancer patient prognosis using Kaplan-Meier analysis (Figure 1C)

Read more

Summary

Introduction

Gastric cancer is one of the most common malignant cancers with serious consequences for population health and mortality. The development and use of gastroscopy has dramatically increased diagnosis and treatment, this is most effective in early stage disease [2,3,4], whereas most gastric cancer patients present in the latter stages of disease to the clinic. The prognosis of advanced stage gastric cancer patients is low, with a typical survival period of 8-12 months [6,7,8]. Gastric cancer tumor infiltration and metastasis are key causes of poor patient prognosis [9]. Mechanistic explanations of such effects include oncogene www.aging-us.com activation, tumor suppressor inactivation, and abnormal cellular metabolism. Pan and colleagues found that layilin (LAYN) is a new prognostic and immune infiltration marker in gastric cancer [10]. The application of cancer bioinformatics is a powerful tool in identifying new gastric cancer biomarkers and therapeutic targets

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call